ADOCIA Presents Clinical Results on M1Pram at the 14th International Conference on Advanced Technologies & Treatments for Dia...
June 02 2021 - 1:30AM
Business Wire
Regulatory News:
ADOCIA (Euronext Paris: FR0011184241 – ADOC), a clinical-stage
biopharmaceutical company specialized in the development of
innovative formulations of proteins and peptides, today announced
an oral presentation on the bi-hormonal treatment M1Pram (ADO09) at
the 14th International Conference on Advanced Technologies and
Treatments for Diabetes (ATTD 2021), which will be held June 2-5,
2021 as a virtual event.
You will find below detailed information on the
presentation:
- Session: 0060 - Oral Presentation 02 Date & Time:
Wednesday 2 June 7.45pm – 7.55pm CEST Room: Hall B
Oral Presentation: #498 - ADO09, A CO-FORMULATION OF PRAMLINTIDE
AND INSULIN A21G IMPROVES POST-PRANDIAL GLUCOSE (PPG) VERSUS
INSULIN ASPART IN TYPE 1 DIABETES (T1D) Duration: 10 min
About ATTD
ATTD a scientific program that brings together renowned
international experts to discuss major advances in diabetes
treatments, technological innovations and present the latest
developments in new insulin analogues, delivery systems, pumps,
glucose sensors, closed-loop systems and more.
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes,
obesity and metabolic diseases. In the diabetes field, Adocia’s
portfolio of injectable treatments is among the largest and most
differentiated of the industry, featuring five clinical-stage
products and several pre-clinical products. The proprietary
BioChaperone® technological platform is designed to enhance the
effectiveness and/or safety of therapeutic proteins while making
them easier for patients to use. Adocia customizes BioChaperone to
each protein for a given application.
Adocia’s clinical pipeline includes four novel insulin
formulations for prandial treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid acting
insulin lispro (BioChaperone® Combo) and one combination of a
prandial insulin with amylin analog pramlintide M1Pram. The
clinical pipeline also includes an aqueous formulation of human
glucagon (BioChaperone® Glucagon) for the treatment of
hypoglycemia.
Adocia preclinical pipeline includes bi-hormonal combinations
for diabetes treatment: two combinations of rapid acting insulin
analogs and Pramlintide (BioChaperone® Lispro Pram and
BioChaperone® Aspart Pram), a combination of insulin glargine with
GLP-1 receptor agonists (BioChaperone® Glargine Liraglutide). In
addition, there are two bi-hormonal products for the treatment of
obesity: a combination of glucagon and exenatide (BioChaperone®
Glucagon Exenatide) and a combination of pramlintide and exenatide
(PramExe).
Adocia recently added a preclinical program to its pipeline with
a cell therapy initiative focused on development of a hydrogel
scaffold for use in people with type 1 diabetes. The first patent
application supporting this program has been filed.
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Universal Registration Document filed
with the French Autorité des marchés financiers on April 20, 2021
(a copy of which is available at www.adocia.com) and to the
development of economic conditions financial markets and the
markets in which Adocia operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to Adocia or not currently considered material by Adocia. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance, or achievements of Adocia to be
materially different from such forward-looking statements. This
press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
Adocia shares in any jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210601005922/en/
Adocia Gérard Soula CEO
contactinvestisseurs@adocia.com +33 4 72 610 610 www.adocia.com
MC Services AG Adocia Press Relations Europe Raimund
Gabriel Managing Partner adocia@mc-services.eu +49 89 210 228
0
The Ruth Group Adocia Investor Relations USA James
Salierno Vice-President jsalierno@theruthgroup.com +1 646 536
7035
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2024 to May 2024
Adocia (EU:ADOC)
Historical Stock Chart
From May 2023 to May 2024